12/11/07

SAN DIEGO - December 11, 2007 - SpineOvations, a San Diego-based medical technology company focused on the development of new and innovative products, announced today that it has named Robert R. Anglea to its Board of Directors.

Anglea, who most recently served as President of PerMedics, Inc., brings to SpineOvations' Board more than 26 years of corporate leadership experience with healthcare technology businesses, including two Fortune 500 companies and three successful launches of emerging healthcare organizations.

Prior to signing on as President of PerMedics in 1998, Anglea served as President of Strategic Direction and as President of Kendall McGaw Pharmaceuticals, where he was the corporate founder of that company's injectable pharmaceuticals business. Early in his career Anglea held various management positions with American Hospital Supply. In his career to date, Anglea has been directly involved in more than a dozen acquisitions (from both sides of the table) of health-related organizations.

SpineOvations is focused on the development of biocompatible injectables for the stabilization of spinal disc integrity and for other orthopedic applications, including non-surgical connective tissue repair. The company's technology platform consists of a novel, non-surgical application for identifying and treating spinal disc tears or fissures to seal and stabilize the structural integrity of the spinal disc.

SpineOvations' new treatment concept integrates the use of discography with the administration of the company's DiscSeal(TM), an injectable agent for soft tissue engineering, designed to fill and seal the disc defect and provide internal disc stabilization and pain relief for the millions of patients with chronic back pain as a result of internal disc derangement (IDD). This innovative approach offers the potential to provide a cost-effective treatment option for patients with chronic back pain that will delay or possibly prevent the need for more invasive treatments such as surgery for spinal fusion or disc replacement.

"Rob has a unique eye for potential in health care-related businesses," said SpineOvations CEO, M. Ross Simmonds. "His experience as a builder of strategic partnerships, market targeting, corporate finance in our sector and focused goal direction with bottom line orientation is sure to be a great asset to our company. We're confident his guidance as part of our board will be a tremendous asset as we move forward into the rapidly evolving spine device marketplace."

# # #

SpineOvations is a San Diego-based, privately held medical device company focused on the development of novel, biocompatible injectables for the stabilization of spinal disc integrity and for other orthopedic applications including non-surgical connective tissue repair. The company’s technology platform consists of a novel non-surgical application for identifying and treating spinal discs that have tears or fissures in order to seal the defect and improve structural integrity.

SpineOvation’s DiscSeal™ is a percutaneous injection treatment for patients with Internal Disc Derangement (IDD) and suffering from chronic, discogenic lower back pain. DiscSeal is designed to be an early-stage treatment for those patients who have failed conservative care and who are not yet candidates for the invasive surgical treatment options of total disc replacement or spinal fusion, the largest segment of the spine market. For more information, visit : http://www.spineovations.com

CONTACT: Paul Williams of MediaLine Communications for SpineOvations, 949/916-6880; medialine2@aol.com